We found that even after adjustment for the duration of T2DM and level of glycemic control, the use of insulin in HFrEF patents to treat diabetes still led to a 2-fold increase in the risk of the primary composite outcome, indicating that the negative prognostic effect of insulin is unlikely to be changed. The gene discussed is INS; the disease is diabetes mellitus.